ClinicalTrials.gg
RecruitingNCT07782619Updated Sep 2, 2026

Agreement of Two OCT Biometers: A Pilot Study

An observational study in Anterior Segment of Eye, Axial Length and Biometrics Measurement, sponsored by Alcon Research. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Alcon Research (part of Alcon) · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
21 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the measurements obtained with two different biometers, UNITY Dx and Anterion. In eye care, a biometer is a device that uses laser technology to take highly precise measurements of the eye's internal structures. It is most frequently used to help determine the exact power of the intraocular lens (IOL) needed before cataract removal.

Read the detailed description

The study population will consist of male and female adult subjects with a normal cornea (up to 10 subjects), keratoconus (up to 10 subjects), prior corneal laser vision correction (up to 10 subjects), current and habitual contact lens wear (up to 10 subjects), or dry eye (up to 10 subjects). In this single visit study, subjects will have data collected on one eye (unilateral) only. If both eyes meet the entry criteria, the right eye will be designated as the study eye.

02

Conditions studied

  • Anterior Segment of Eye
  • Axial Length
  • Biometrics Measurement

Keywords

  • Biometer
03

In context

Lead sponsor

Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.

Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Cohorts will be selected from approximately one investigative site located in the United States.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have healthy, clear corneas for the normal cohort;
  • Have documented keratoconus for the keratoconus cohort;
  • Have reported use of daily contact lens use for the contact lens cohort;
  • Have documented dry eye, consisting of signs and symptoms for the dry eye cohort;
  • Has had previous keratorefractive surgery for the post-refractive surgery cohort;
  • Able to comprehend and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Active ocular infection or inflammation;
  • Unable to fixate due to nystagmus or other eye movement abnormality (e.g., significant strabismus);
  • Any ocular disease and/or condition that, in the investigator's clinical judgment, may put the subject at significant risk, may compromise study result or may interfere significantly with the subject's participation in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Normal Corneas

    This cohort will enroll subjects with normal corneas.

    Device: UNITY DX · Device: ANTERION

  • Keratoconus

    This cohort will enroll subjects with keratoconus.

    Device: UNITY DX · Device: ANTERION

  • Prior Corneal Laser Vision Correction

    This cohort will enroll subjects with prior corneal laser vision correction.

    Device: UNITY DX · Device: ANTERION

  • Current and Habitual Contact Lens Wear

    This cohort will enroll subjects with current and habitual contact lens wear.

    Device: UNITY DX · Device: ANTERION

  • Dry Eye

    This cohort will enroll subjects with dry eye.

    Device: UNITY DX · Device: ANTERION

Interventions

  • DeviceUNITY DX

    Investigational non-contact, non-invasive ophthalmic imaging and analysis device used for visualization of ocular structures and their optical properties

  • DeviceANTERION

    Commercially available non-contact, non-invasive ophthalmic imaging and analysis device used for visualization of ocular structures and their optical properties

06

What researchers measure

Primary outcomes

  1. Regression-Based Axial Length (R-AL)

    Regression-based Axial Length (R-AL) is the distance from the anterior surface of the cornea to the retina at the back of the eye, measured along the visual axis. R-AL will be measured by the device and reported in microns.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Aug 24, 2026
StartActual
Aug 17, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07782619
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Aug 17, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Alcon Call Center
Contact
alcon.medinfo@alcon.com
1-888-451-3937
Clinical Trial Lead, Surgical
study director · Alcon Research, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion